Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.54 |
| ▸ | MPC2 | O95563 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4165069 | 0.99 | PPARG (0.53) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Hydrochloric Acid SCHEMBL6064786 | 0.99 | PPARG (0.53) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6543635 | 0.95 | PPARG (0.49) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Hydrochloric Acid SCHEMBL6544486 | 0.94 | PPARG (0.48) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6896704 | 0.93 | PPARG (0.51) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Hydrochloric Acid SCHEMBL4177074 | 0.92 | PPARG (0.51) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL7243299 | 0.90 | FFAR1 (0.49) | PPARGFFAR1PPARA | |
| Hydrochloric Acid SCHEMBL6701459 | 0.90 | PPARG (0.47) | PPARGFFAR1PPARA | |
| SCHEMBL6543694 | 0.89 | PPARG (0.46) | PPARGFFAR1PPARA | |
| Hydrochloric Acid SCHEMBL7248266 | 0.89 | FFAR1 (0.48) | PPARGFFAR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092524-A1 | Agent for Enhancing Corneal Epithelial Barrier Function | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-04-21 | — | — | US | claimed |
| EP-0753298-B2 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO CO (JP) | 2011-02-16 | — | — | EP | claimed |
| EP-1679074-B1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDER | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-12-08 | — | — | EP | claimed |
| US-20090227493-A1 | COMBINED DRUG FOR TREATING DIABETES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-10 | — | — | US | claimed |
| US-20090137626-A1 | Pharmaceutical Composition Containing PPARgamma Agonist | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | claimed |
| US-20090088462-A1 | Pharmaceutical Composition for Enhancing Adiponectin Production | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-04-02 | — | — | US | claimed |
| EP-1990053-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ADIPONECTIN PRODUCTION | Daiichi Sankyo Company, Limited (JP) | 2008-11-12 | — | — | EP | claimed |
| US-7358255-B2 | Therapeutic agent for keratoconjunctival disorder | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-04-15 | — | — | US | claimed |
| EP-1905450-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PPAR GAMMA AGONIST | Daiichi Sankyo Company, Limited (JP) | 2008-04-02 | — | — | EP | claimed |
| EP-1889618-A1 | COMBINED DRUG FOR TREATING DIABETES | Daiichi Sankyo Company, Limited (JP) | 2008-02-20 | — | — | EP | claimed |
| EP-0753298-B1 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO CO (JP) | 2001-11-21 | — | — | EP | claimed |
| EP-0745600-B1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | claimed |
| WO-2000041690-A9 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | UNIV CALIFORNIA (US) | 2001-10-11 | — | — | WO | claimed |
| US-6159997-A | Treatment of arteriosclerosis and xanthoma | SANKYO COMPANY, LIMITED (JP) | 2000-12-12 | — | — | US | claimed |
| US-6150371-A | WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE | SANKYO COMPANY, LIMITED (JP) | 2000-11-21 | — | — | US | claimed |
| WO-2000041690-A1 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-20 | — | — | WO | claimed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | claimed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | claimed |
| EP-0753298-A1 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO COMPANY LIMITED (JP) | 1997-01-15 | — | — | EP | claimed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137626-A1 | Pharmaceutical Composition Containing PPARgamma Agonist | PPARG, PPARA, PPARD | PPARG 1/4885MPC2 359/4885CYP2C8 588/4885 |
| US-20090088462-A1 | Pharmaceutical Composition for Enhancing Adiponectin Production | ADIPOR1, ADIPOR2, FABP4 | PPARG 37/4885MPC2 1615/4885CYP2C8 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.